High level of agreement in a fixed vs. live cell-based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting.

ABSTRACT:

Introduction

As recognition of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease becomes more widespread, the importance of appropriately ordering and interpreting diagnostic testing for this antibody increases. Several assays are commercially available for MOG testing, and based on a few small studies with very few discrepant results, some have suggested that live cell-based assays (CBA) are superior to fixed CBA for clinical MOG antibody testing. We aimed to determine the real-world agreement between a fixed and live CBA for MOG using two of the most commonly available commercial testing platforms.

Methods

We compared paired clinical samples tested at two national clinical reference laboratories and determined the real-world agreement between the fixed

SUBMITTER: Smith TL 

PROVIDER: S-EPMC10368875 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature